A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers

Trial Profile

A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Vapendavir (Primary) ; Vapendavir (Primary) ; Vapendavir (Primary)
  • Indications Rhinovirus infections
  • Focus Pharmacokinetics
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 14 Sep 2016 Results of the bioavailability study were published in an Aviragen Therapeutics financial report.
    • 13 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top